Tailoring Medication to DNA Leads to 30% Fewer Side Effects
Complete the form below to unlock access to ALL audio articles.
According to an international group of researchers including a team from the University of Liverpool, patients experience 30% fewer side effects when medication doses are tailored to their DNA.
The group’s study, published in The Lancet, is the first to demonstrate the practical application of using a panel of genes to tailor drug prescription to the individual.
The ‘one-size-fits all’ approach for prescribing medication as currently used leads to problems with the effectiveness and safety of medicines. Due to variations in our genetic information, patients may respond differently to a specific drug - for example, some individuals process medication faster than others and, as a result, require a higher dose to achieve the necessary effect. Others process it slower, which can lead to side effects. To facilitate this, the researchers developed a ‘DNA medication pass’ that associates a patient’s genetic profile to drugs whose processing is influenced by DNA. Scanning the pass enables doctors and pharmacists to know what the optimal medication is, and its dose, for the individual being treated.
Standard vs adjusted dose
The Lancet study found that patients who actively make use of the medication pass, and whose drugs and doses are adjusted according to their DNA, experienced 30% fewer serious side effects than patients who were prescribed a standard dose of medication. Approximately 7000 patients from seven European countries were assessed over several medical specialities, including oncology, cardiology, psychiatry and general medicine.
Want more breaking news?
Subscribe to Technology Networks’ daily newsletter, delivering breaking science news straight to your inbox every day.Subscribe for FREE
Not only did patients holding the DNA medication pass experience fewer side effects, they also expressed great satisfaction with the pass itself. According to the researchers, the pass gives patients the feeling of being more in control, as they become actively involved in their personalised treatment.
Liverpool-only UK study site
Liverpool was the only UK site to take part in this multi-national randomised study, recruiting 1037 patients from the Royal Liverpool University Hospital and from two GP surgeries. Researchers at the University of Liverpool worked with the co-ordinator in obtaining funding from the EU Commission, and also assisted with the design of the trial - including the use of the Liverpool Causality Assessment Tool in assessing causality of the adverse reactions, which was important for determining the primary outcome measure used in the study.
Professor Sir Munir Pirmohamed, who was the UK principal investigator, and chaired the committee that published the personalised prescribing report, said: “This is a large landmark randomised study which shows that pharmacogenomic testing using a comprehensive genotyping panel can prevent adverse drug reactions, an outcome measure which is clinically important to individual patients and to healthcare systems. A 30% reduction in adverse reactions with a single intervention is remarkable. This is also consistent with the Personalised Prescribing report that was published by the Royal College of Physicians and British Pharmacological Society, which called for the implementation of pharmacogenomics into the NHS.”
Could the DNA medication pass become part of standard care?
The study was coordinated by Henk-Jan Guchelaar, Professor of Clinical Pharmacy at Leiden University Medical Center. He has conducted research in the field of pharmacogenetics for over 20 years. “For the first time we have proven that a ‘tailored’ strategy works at a large scale within clinical practice. There is now enough evidence for us to proceed with implementation,” says Guchelaar.
Figuring out the subsequent stages of the implementation process also raises various questions which will be different in each country. In the UK, the steps for implementing pharmacogenomic testing in the NHS have been outlined in the Personalised Prescribing report. Guchelaar notes. “By adapting implementation to suit each country’s healthcare system, we can make treatment more effective and safer for millions of patients”.
Reference: Swen JJ, Wouden CH van der, Manson LE, et al. A 12-gene pharmacogenetic panel to prevent adverse drug reactions: an open-label, multicentre, controlled, cluster-randomized crossover implementation study. The Lancet. 2023;401(10374):347-356. doi: 10.1016/S0140-6736(22)01841-4
This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.